You have printed or saved this information from www.HorizonNB.ca, the website for the Horizon Health Network
Kidney Disease
Kidney Disease
DIALIZE-Outcomes: An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrhythmia-Related Cardiovascular Outcomes in Participants on Chronic Hemodialysis with Recurrent Hyperkalemia
We are doing this study to learn more about the benefits and risks of treating hyperkalemia (high levels of potassium in the blood) in people on hemodialysis and to better understand the studied disease and related health problems. The treatment we are studying is sodium zirconium cyclosilicate (SZC). In this study, we will record how often people suffer sudden cardiac death, stroke, and hospitalization/intervention/Emergency Department (ED) visits due to abnormal heart rhythms. We want to see if treatment with SZC reduces the risk of these things happening.
- Condition: Hyperkalemia
- Study ID: NCT04847232
- Sponsor: AstraZeneca
- Location: Saint John Regional Hospital
- Horizon Principal Investigator: Dr. Martin MacKinnon
- To participate, call the research coordinator at: 506-648-6648 and refer to study file #101273
ZENITH: A Phase 2b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/Min/1.73 m^2
We are doing this study to learn more about the effects of an experimental drug called zibotentan, when taken by itself and taken in combination with another drug called dapagliflozin, by patients with chronic kidney disease. The study aims to measure the effect of zibotentan and dapagliflozin on the amount of albumin (protein) present in the urine of patients with chronic kidney disease (CKD) and will measure how safe and tolerable these drugs are in CKD patients.
- Condition: Chronic kidney disease
- Study ID: NCT04724837
- Sponsor: AstraZeneca
- Location: Saint John Regional Hospital
- Horizon Principal Investigator: Dr. Martin MacKinnon
- To participate, call the research coordinator at: 506-648-6648 and refer to study file #101271